Technotes, Publications, Technology platforms and FAQs
Publications and Technotes
ACS Biomarker aims to advance translational research by publishing high-quality data in peer reviewed journals. See our technotes for details on our measurement and analysis pipeline.
Publications
Prognostic value of circulating microRNAs on heart failure-related morbidity and mortality in two large diverse cohorts of general heart failure patients.
Bayés-Genis A. et al. Eur J Heart Fail. 2017 Sep 26
Serially measured circulating microRNAs and adverse clinical outcomes in patients with acute heart failure.
van Boven N. et al. Eur J Heart Fail. 2017 Sep 26
Circulating miRNA Analysis Guidelines
De Ronde et al. RNA. 2017 May;23(5):811-821
miR-22-3p in heart failure
Van Boven et al. Int J Cardiol. 2017 May 15;235:124-132
Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease?
Creemers EE et al. Circ Res. 2012 Feb 3;110(3):483-95
MiR423-5p as a circulating biomarker for heart failure.
Tijsen et al. Circ Res. 2010 Apr 2;106(6):1035-9.
Exosome Extractions
Sample submission
Sample preparation
Technotes
Cardio-Onco Biomarker Panel
miRNA profiling
TECHNOLOGY PLATFORMS
RNA profiling platform
To obtain high quality results we have chosen the superior miRNA platform of Quantabio for our biomarker services. This platform offers a cost-effective method to measure multiple RNA molecules from a single RT reaction. The open technology provides flexibility to design your own assay primers and eliminates inefficient stem-loop priming and costly hydrolysis probes. It has been reported as one of the best miRNA profiling platforms and guarantees to deliver reliable results.
